Response to Degarelix After Resistance to Leuprolide in a Patient With Metastatic Prostate Cancer

Response to Degarelix After Resistance to Leuprolide in a Patient With Metastatic Prostate Cancer

J Adv Pract Oncol 2012;3:299–303 Androgen-deprivation therapy (ADT) is a common treatment for prostate cancer, as the androgen receptor (AR) plays a role in the development of this malignancy. Androgen-deprivation therapy agents can be classified as gonadotropin-releasing hormone (GnRH) agonists or GnRH antagonists. The most common GnRH agents in use are the GnRH agonists. However, these agents...

Complete Radiologic Response in Metastatic Castration-Resistant Prostate Cancer Treated with Cabazitaxel

Sustained complete response to CTLA-4 blockade in a patient with metastatic, castration-resistant prostate cancer.

We present the case of a man with metastatic, castration-resistant prostate cancer, who had a complete prostate-specific antigen (PSA) response after 2½ doses of ipilimumab. His treatment course was complicated by diarrhea and autoimmune hepatitis, both of which resolved within 4 months. Sera and biopsy specimens were accessed, and sera from pretreatment and day 113 were analyzed. Augmented ant...

Cost-effectiveness analysis comparing degarelix with leuprolide in hormonal therapy for patients with locally advanced prostate cancer.

Degarelix, approved in the USA in 2008, is a gonadotropin-releasing hormone antagonist, representing one of the latest additions to androgen deprivation therapy (ADT). ADT is used as first-line therapy for locally advanced or metastatic prostate cancer with the aim to reduce testosterone to castrate levels. Like other gonadotropin-releasing hormone-antagonists, degarelix treatment results in ra...

Hypotensive response after resistance exercise leading to failure and not to failure in trained men

Hypertension is epidemic disease which post-exercise hypotension (PEH) is useful strategies for hypertension. The aim of present study was to investigate the effects of resistance exercise leading to failure (REF) and resistance exercise not to failure (NREF) on PEH phenomenon in trained men. Eight trained men (age: 22.12±1.81 yr; height: 179±3.44 cm; weight: 73.82±4.29 kg;...